Fatalt leversvigt efter pembrolizumab i kombination med carboplatin og pemetrexed

Rasmus Strøm Risbjerg; Niels Kristian Aagaard; Lisbet Grønbæk; Signe Hertz Hansen; Katja Maretty Kongstad; Konstantin Kazankov

doi:10.61409/V06240442

Fatalt leversvigt efter pembrolizumab i kombination med carboplatin og pemetrexed

Rasmus Strøm Risbjerg, Niels Kristian Aagaard, Lisbet Grønbæk, Signe Hertz Hansen, Katja Maretty Kongstad, Konstantin Kazankov^*

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

Abstract

Immunotherapy-induced hepatitis is a well-known and relatively common side effect of immune checkpoint inhibitors. It is usually mild to moderate and responds well to corticosteroids with a full recovery. However, in rare cases, severe liver injury may develop, leading to fulminant liver failure. In this case report, we present a case of acute fulminant liver failure with a fatal outcome despite adequate treatment in a 67-year-old male following a combination therapy of carboplatin, pemetrexed, and pembrolizumab for metastatic lung cancer.

Bidragets oversatte titel	Fatal hepatitis after pembrolizumab in combination therapy with carboplatin and pemetrexed
Originalsprog	Dansk
Artikelnummer	V06240442
Tidsskrift	Ugeskrift for Læger
Vol/bind	186
Nummer	51
ISSN	0041-5782
DOI	https://doi.org/10.61409/V06240442
Status	Udgivet - 16 dec. 2024

Emneord

Humans
Male
Aged
Pemetrexed/adverse effects
Antibodies, Monoclonal, Humanized/adverse effects
Carboplatin/adverse effects
Antineoplastic Combined Chemotherapy Protocols/adverse effects
Lung Neoplasms/drug therapy
Fatal Outcome
Chemical and Drug Induced Liver Injury/etiology
Liver Failure, Acute/chemically induced
Antineoplastic Agents, Immunological/adverse effects

Adgang til dokumentet

10.61409/V06240442Licens: CC BY-NC-ND

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{82233c7a0ec24333808c573e288a1eaf,

title = "Fatalt leversvigt efter pembrolizumab i kombination med carboplatin og pemetrexed",

abstract = "Immunotherapy-induced hepatitis is a well-known and relatively common side effect of immune checkpoint inhibitors. It is usually mild to moderate and responds well to corticosteroids with a full recovery. However, in rare cases, severe liver injury may develop, leading to fulminant liver failure. In this case report, we present a case of acute fulminant liver failure with a fatal outcome despite adequate treatment in a 67-year-old male following a combination therapy of carboplatin, pemetrexed, and pembrolizumab for metastatic lung cancer.",

keywords = "Humans, Male, Aged, Pemetrexed/adverse effects, Antibodies, Monoclonal, Humanized/adverse effects, Carboplatin/adverse effects, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Lung Neoplasms/drug therapy, Fatal Outcome, Chemical and Drug Induced Liver Injury/etiology, Liver Failure, Acute/chemically induced, Antineoplastic Agents, Immunological/adverse effects",

author = "Risbjerg, {Rasmus Str{\o}m} and Aagaard, {Niels Kristian} and Lisbet Gr{\o}nb{\ae}k and Hansen, {Signe Hertz} and Kongstad, {Katja Maretty} and Konstantin Kazankov",

year = "2024",

month = dec,

day = "16",

doi = "10.61409/V06240442",

language = "Dansk",

volume = "186",

journal = "Ugeskrift for L{\ae}ger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "51",

}

TY - JOUR

T1 - Fatalt leversvigt efter pembrolizumab i kombination med carboplatin og pemetrexed

AU - Risbjerg, Rasmus Strøm

AU - Aagaard, Niels Kristian

AU - Grønbæk, Lisbet

AU - Hansen, Signe Hertz

AU - Kongstad, Katja Maretty

AU - Kazankov, Konstantin

PY - 2024/12/16

Y1 - 2024/12/16

N2 - Immunotherapy-induced hepatitis is a well-known and relatively common side effect of immune checkpoint inhibitors. It is usually mild to moderate and responds well to corticosteroids with a full recovery. However, in rare cases, severe liver injury may develop, leading to fulminant liver failure. In this case report, we present a case of acute fulminant liver failure with a fatal outcome despite adequate treatment in a 67-year-old male following a combination therapy of carboplatin, pemetrexed, and pembrolizumab for metastatic lung cancer.

AB - Immunotherapy-induced hepatitis is a well-known and relatively common side effect of immune checkpoint inhibitors. It is usually mild to moderate and responds well to corticosteroids with a full recovery. However, in rare cases, severe liver injury may develop, leading to fulminant liver failure. In this case report, we present a case of acute fulminant liver failure with a fatal outcome despite adequate treatment in a 67-year-old male following a combination therapy of carboplatin, pemetrexed, and pembrolizumab for metastatic lung cancer.

KW - Humans

KW - Male

KW - Aged

KW - Pemetrexed/adverse effects

KW - Antibodies, Monoclonal, Humanized/adverse effects

KW - Carboplatin/adverse effects

KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects

KW - Lung Neoplasms/drug therapy

KW - Fatal Outcome

KW - Chemical and Drug Induced Liver Injury/etiology

KW - Liver Failure, Acute/chemically induced

KW - Antineoplastic Agents, Immunological/adverse effects

UR - http://www.scopus.com/inward/record.url?scp=85214589797&partnerID=8YFLogxK

U2 - 10.61409/V06240442

DO - 10.61409/V06240442

M3 - Tidsskriftartikel

C2 - 39749629

SN - 0041-5782

VL - 186

JO - Ugeskrift for Læger

JF - Ugeskrift for Læger

IS - 51

M1 - V06240442

ER -

Fatalt leversvigt efter pembrolizumab i kombination med carboplatin og pemetrexed

Abstract

Emneord

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater